ASH highlights in CLL and lymphoma by Dr Andrew Zelenetz

Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY provides an overview of a few new drugs presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL, in the fields of chronic lymphocytic leukemia (CLL) and lymphoma. Dr Zelenetz talks about venetoclax (ABT-199), a BH3 mimetic used as front-line therapy of CLL. As for lymphoma, Dr Zelenetz draws attention to cell-free DNA studies that can provide additional information at diagnosis or help manage treatment and progression of the disease.